Stable renal function after islet transplantation: Importance of patient selection and aggressive clinical management

Transplantation

Volumn 87, Issue 5, 2009, Pages 681-688

  Leitão, Cristiane B ^a,b   Cure, Pablo ^a   Messinger, Shari ^a   Pileggi, Antonello ^a   Lenz, Oliver ^a   Froud, Tatiana ^a   Faradji, Raquel N ^a   Selvaggi, Gennaro ^a,c   Kupin, Warren ^a   Ricordi, Camillo ^a,c   Alejandro, Rodolfo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Albuminuria; Blood pressure; Islet transplantation; Kidney function; Lipids

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; GLYCOSYLATED HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG MONITORING; DRUG SUBSTITUTION; ECZEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MACROALBUMINURIA; MALE; MICROALBUMINURIA; MIGRAINE; MOUTH ULCER; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS ISLET TRANSPLANTATION; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; DIABETIC NEPHROPATHY; KIDNEY FUNCTION TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; ONSET AGE; PHYSIOLOGY; PROTEINURIA; STANDARD;

ADULT; AGE OF ONSET; ALBUMINURIA; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PATIENT SELECTION; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 65649131891     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819279a8     Document Type: Article

References (34)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977.
2. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643.
3. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypogly-caemia in 1076 adult patients with type 1 diabetes: Influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20: 479.
4. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 5: 2037.
5. Poggioli R, Faradji RN, Ponte G, et al. Quality of life after islet transplantation. Am J Transplant 2006; 6: 371.
6. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318.
7. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
8. Maffi P, Bertuzzi F, De Taddeo F, et al. Kidney function after islet transplant alone in type 1 diabetes: Impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007; 30: 1150.
9. Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: Four-year observational study. Am J Transplant 2007; 7: 91.
10. Fung MA, Warnock GL, Ao Z, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: An interim report. Transplantation 2007; 84: 17.
11. Stadler M, Auinger M, Anderwald C, et al. Long-term mortality and incidence of renal dialysis and transplantation in type 1 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 3814.
12. Pileggi A, Ricordi C, Kenyon NS, et al. Twenty years of clinical islet transplantation at the Diabetes Research Institute - University of Miami. Clin Transpl 2004:177.
13. Cure P, Pileggi A, Faradji RN, et al. Cytomegalovirus infection in a recipient of solitary allogeneic islets. Am J Transplant 2006; 6: 1089.
14. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31(suppl 1): S12.
15. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461.
16. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499.
18. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69.
19. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830.
20. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
21. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35(3 suppl): 52S.
22. Liptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006; 2: 398.
23. Creput C, Blandin F, Deroure B, et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 2007; 13: 1004.
24. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006; 21: 488.
25. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429.
26. Laugharne M, Cross S, Richards S, et al. Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines. Transplantation 2007; 83: 1635.
27. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. JAm Soc Nephrol 2001; 12: 1059.
28. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164.
29. Campbell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007; 7: 1242.
30. Costa LA, Canani LH, Lisboa HR, et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004; 21: 252.
31. Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 2008; 23: 1919.
32. Rostaing L, Tran-Van T, Cisterne JM, et al. Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. Transplant Proc 1998; 30: 1282.
33. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 2000; 49: 1399.
34. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(2 suppl 2): S12.